Neurology

Rimegepant Meets Primary End Point in Episodic Migraine




Researchers noted at least a 50% reduction from baseline in mean number of moderate to severe migraine days per month in 48% of the rimegepant group.

Source link






Related posts

Why the Discovery of ‘LATE’ Dementia Is Important

Newsemia

The Connection Between Sleep & Back Pain

Newsemia

Green Light Therapy and Migraines: Will Research Translate to Real-World Use?

Newsemia

This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy